Back to Search

A Phase 1/2, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Subjects With Relapsed or Refractory B Cell Malignancies

  • Protocol Number: 202302040
  • Principal Investigator: Ghobadi, Armin
  • Cancer Types: Gene & Cellular Immunotherapy, Leukemia, Myeloma, and Hematologic, Lymphoma

For more information on this trial, contact us here:

[email protected]

Brief Summary

Protocol Interventions